featured
Venetoclax/Obinutuzumab vs Chlorambucil/Obinutuzumab for Previously Untreated CLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (CLL14): Follow-Up Results From a Multicentre, Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2020 Sep 01;21(9)1188-1200, O Al-Sawaf, C Zhang, M Tandon, A Sinha, AM Fink, S Robrecht, O Samoylova, AM Liberati, J Pinilla-Ibarz, S Opat, L Sivcheva, K Le Dû, LM Fogliatto, CU Niemann, R Weinkove, S Robinson, TJ Kipps, E Tausch, W Schary, M Ritgen, CM Wendtner, KA Kreuzer, B Eichhorst, S Stilgenbauer, M Hallek, K FischerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.